Preliminary findings from a randomized trial showed promising results from dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature

Commentary: KEYNOTE-811: Pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer – Vall d’Hebron University Hospital

Commentary on Twitter

Nature research paper: Combining immunotherapy with chemotherapy and targeted agents has the potential to improve the outcome of patients with advanced HER2-positive gastric tumours https://t.co/CNAgZObuTS pic.twitter.com/FWGwQzf4ze

— nature (@Nature) December 15, 2021